Browsing by Subject
Now showing items 1-20 of 20
-
Antimicrobial defined daily dose in neonatal population
(Elsevier, 2022-02) -
Finding MYCure
(Taylor and Francis, 2019-06-20) -
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
(American Society of Clinical Oncology, 2021-06-20) -
Overnight switch from levetiracetam to brivaracetam: safety and tolerability
(Elsevier, 2021) -
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor
(Massachusetts Medical Society, 2017-03-23) -
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
(American Society of Clinical Oncology, 2022-02-10)